Creative Commons Attribution-Noncommercial-Sharealike License

Download as pdf or txt
Download as pdf or txt
You are on page 1of 48

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License.

Your use of this


material constitutes acceptance of that license and the conditions of use of materials on this site.

Copyright 2006, The Johns Hopkins University and Gary Ketner. All rights reserved. Use of these materials
permitted only in accordance with license rights granted. Materials provided AS IS; no representations or
warranties provided. User assumes all responsibility for use, and all liability related thereto, and must independently
review all materials for accuracy and efficacy. May contain materials owned by others. User is responsible for
obtaining permissions for use from third parties as needed.

Host Response to Infection:


The Immune Response and Vaccination
Gary Ketner, PhD
Johns Hopkins University

Section A
Introduction to Innate Immunity

The Immune System

Central to survival after infection


Central to public health
Immunity can be manipulated to protect both
individuals and populations by vaccination
Effective use of vaccination depends upon knowledge
of immune system function
Nature of the vaccine (live, subunit, vectored)
Characteristics of the type of immunity induced
Target antigens

Innate Immunity

Inborn
Effective without prior exposure to an infectious agent
Nonspecific
First-line defense

Continued

Innate Immunity

Physical barriers
Skin
Cornea
Mucus layers (with
clearance)
Outflow (urine, for
example)
Chemical barriers
Stomach acid
Fatty acids on skin
Lysozyme in tears

Active mechanisms
Intracellular
X Interferons
X Apoptosis
Organismal
X Complement
X Phagocytosis

Phagocytosis

Active process that destroys invading pathogens


Mediated by specialized cells (phagocytes)
Macrophages, neutrophils
Phagocytes engulf potential pathogens
Efficient engulfment depends on receptors for
common bacterial cell wall components
Once engulfed, pathogens are killed and digested
Some pathogens are resistant (TB)

Continued

Phagocytosis

Active process that destroys


invading pathogens
Mediated by specialized cells
(phagocytes)
Macrophages, neutrophils
Phagocytes engulf potential
pathogens
Efficient engulfment
depends on receptors for
common bacterial cell
wall components
Once engulfed, pathogens are
killed and digested

Phagocytosis

Phagocytes are located


in strategic places
Skin, blood, gut
Phagocytes are
chemotactic (attracted
to sites of injury)
Phagocytes can be
activated to become
better killers

Section B
Effector Mechanisms of Adaptive Immunity

Adaptive Immunity

Arises as a
consequence of
exposure to a
particular target
(virus, protein, toxin)
Specific for that target
Arises after a delay of
a few days
Potent
Exhibits memory
Rapid, large
reappearance upon
a second exposure
11

Adaptive Immunity Primary and Secondary Responses

12

Adaptive Immunity

Humoral: mediated by protein molecules called


antibodies
Cell-mediated immunity (CMI): due to the action of
specialized immune system cells

13

Humoral Immunity

Mediated mostly by protein molecules called


antibodies (Ab), also called immunoglobulin (Ig)
Antibodies generally are found in extracellular fluids
Blood, lymph, mucus
Antibodies are active against agents with an
extracellular phase, including some viruses, toxins, and
bacterial infections
Not all pathogens have obligatory extracellular
phases
X In some cases, extracellular exposure is brief
X Antibodies tend to be ineffective against such
agents
14

Antigen Binding by Antibody

Antibodies act by physically


binding to their targets called
antigens (Ag)
Antibody binding to antigen
occurs because of a close
physical fit between the
antibody and the target
antigen (epitope)
Binding is extremely
specifica given antibody
binds only to one (or a few
closely related) antigens
Binding results in inactivation
or destruction of the target

Ab

Antigen
(lysozyme)

15

Antibody Structure (IgG)

Four protein chains


Two heavy
Two light
The heavy chains
are identical to
each other
The light chains are
identical to each
other
The chains are held
together by disulphide
bonds
Continued

16

Antibody Structure (IgG)

Each chain has


constant (C) and
variable (V) regions
The variable regions
differ among antibody
species in amino acid
sequenceand therefore
shape
Antibodies bind antigens
by the variable regions
The variation in shape is
responsible for differences in
specificity of different antibody species
Continued

17

Antibody Structure (IgG)

It is estimated that there


can be about 1011
different variable region
amino acid sequences,
and so about 1011
antibody specificities
At a given time, about
109 are found in an
individual
Antibody diversity is
generated by DNA
rearrangements that
occur during immune
development

18

Antibody Structure (IgM, IgA)

There are several different types of antibody, each


with specific functions
Two examples are IgM and IgA, which are
important antibodies on mucosal surfaces

19

Neutralization by Antibody

Neutralization occurs when antibody binding to a


target interferes directly with function

Human rhinovirus
20

Opsonization by Antibody

Phagocytosis can be made much more efficient by


antibody

21

Additional Functions of Antibody

Complement fixation
Antibody-dependent cytotoxicity
Both depend on the binding of Ab to the outside of a
cellular target to recruit effectors that kill the cell

22

Cell-Mediated Immunity (CMI)

The primary effectors of CMI are cytotoxic T cells (killer


T cells, CD8+ T cells, CTLs)
Activated macrophages also participate
Cytotoxic T cells kill other cells
The primary targets of cytotoxic T cells are usually
pathogen-infected cells
Like humoral immunity, CMI depends on specific
recognition of an antigen by a protein: T-cell receptor

23

T-Cell Receptor (TcR)

Primary recognition
molecule in CMI
Similar in structure to
antibody
Two chains
V and C regions
Membrane-bound

24

Recognition by TcR

TcR recognizes antigen


by shape
Recognition is of
antigen fragments,
bound to another
specialized immune
system protein, the
MHC I antigen
This is called
presentation
MHC I is found on the
surface of essentially all
cells
25

Antigen Presentation

The targets of CMI tend


to be pathogen-infected
cells
Presentation is the
consequence of a
specific mechanism:
Processing
Intracellular loading
of MHC I
Transport to the cell
surface

26

Killing by CMI

Antigen is presented
Antigen is recognized by cytotoxic T cell
The T cell releases pore-forming proteins
The target cell dies, killing the internal pathogen

27

Humoral vs. Cell-Mediated Immunity

Humoral immunity
Antibody-mediated
Effective in extracellular spaces
CMI
Mediated by T cells
Effective against intracellular pathogens
Kills infected host cells

28

Section C
Induction of Adaptive Immunity

Induction of an Immune Response

Induction of the humoral and CMI responses involve


parallel mechanisms:
Effectors arise from initially nave precursor cells (B
and T cells)
Precursors bear surface receptors with specificities
generated at random (Ig, TcR)
Nave precursors differentiate (acquire effector
function) because of interaction between antigen
and receptors
Development begins with an interaction between
the pathogen and professional antigen-presenting
cells (APCs)
30

Professional APCs

Situated for immediate interception of pathogens


Biologically tuned to effectively initiate a response
Specialized to deal with different threats

31

Macrophages

Stationed in skin, gut, and


circulation
Phagocytic
Surface receptors are preset
to recognize common
bacterial cell components
Engulf, kill, process, and
present
Present using MHC II

32

B Cells

Stationed in lymph
nodes and in the
circulation
Surface receptor is
membrane-bound
antibody
Antibody specificities are
randomly generated
Antigens binding
stimulates phagocytosis
Antigens are processed
and presented on MHC II
33

Dendritic Cells

Stationed in skin
Particularly susceptible
to infection by viruses
Present internallyproduced antigens on
MHC I

34

Maturation of T Cells

T cells are produced as nave precursors


No effector function
Random TcR specificities
Maturation is triggered by encountering a cell
presenting a recognizable antigen
Maturation of T cells involves primarily:
Acquisition of effector function
Proliferation of cells with specificities that suit the
pathogen at hand (clonal expansion)

35

Maturation of T Cells

Nave T cells circulate, sampling the antigens


presented on APCs
Sampling involves brief physical interaction
between the antigen (in the context of MHC) and
the T cell TcR
If the antigen is not recognized, the interaction is short
lived, and the T cell moves on

36

Maturation of T Cells

If the antigen is recognized, binding is tight and long


lived
Stimulatory signals are exchanged (cytokines)
The T cell proliferates
Effector mechanisms are developed
Memory cells are produced

37

Cytotoxic T Cells and Helper T Cells

There are two kinds of T cells:


Cytotoxic T cells ( TC or CD8+)
Helper T cells ( TH or CD4+)
These differ in function and therefore develop
different effector functions
TC kills virus infected cells and develops cytotoxic
mechanisms discussed earlier
TH assists in the immune response (below) and
develops helper mechanisms (increased ability to
secrete cytokines)

38

Cytotoxic T Cells and Helper T Cells

TH and TC cells arise similarlybut from different nave


precursors
Also, TC development is stimulated by antigen
presented on MHC I by dendritic cells
TH by antigen presented on MHC II

39

Maturation of B Cells

Antibodies are the products of plasma cells, which


mature from B cells
Nave B cells with random surface antibody
specificities circulate, sampling the antigens present
If an antigen recognized by the nave B cell is
encountered, its bind is internalized, and it is
presented on MHC II
Modest proliferation also occurs, and partial
activation toward the plasma cell state
The B cell is now primed for differentiation, needing
only help from a TH cell

40

Maturation of B Cells

The primed B cell continues to circulate, presenting its


processed antigen to passing T cells
Since it presents on MHC II, only TH cells are
interested
When a cognate TH cell is finally encountered, signals
are exchanged (as for T-cell maturation above)
Cell proliferation occurs
Differentiation to plasma cells and IgG production
begins
X (Refinement of specificity)
Memory cells are produced

41

Secondary Immune Response

Arises from memory cells


Arises quickly because the activation steps have
occurred and need not be repeated
Is large because of the increased number of starting
cells

42

Section D
Poliovirus Pathogenesis: A Review

Poliovirus Pathogenesis: A Review

Transmission by fecal-oral route via contaminated


water
Primary replication/multiplication is in lymphoid cells
(specialized cells of the immune system), especially in
the gut
Virus is shed primarily into the gut and is excreted in
the feces
Some virus also enters the blood and reaches other
susceptible cells; these include anterior horn cells
(motor neurons), which innervate muscle
Destruction of these cells can result in paralysis
Disease is not a consequence of an essential step in
the viruss life cycle
44

Immunology and the Polio Vaccine

Two polio vaccines were developed with support from


the March of Dimes campaign initiated in 1938 and
sponsored by President Franklin Roosevelt, a paralytic
polio victim
1. Killed virus (Salk), licensed in 1955
2. Attenuated live virus (Sabin), licensed in 1962

Continued

45

Immunology and the Polio Vaccine

The two vaccines have very different immune


consequences
What immunity is induced by each vaccine?
What APCs are initially involved? how do they
present antigen?
What T cells does each stimulate?
What sort of immunity does each ultimately
produce?

Continued

46

Immunology and the Polio Vaccine

What protection is conferred by each vaccine?


Against disease?
Against viral replication?
Does each of these vaccines protect an individual
against disease?

Continued

47

Immunology and the Polio Vaccine

What practical public health advantages does each


vaccine have?
What is current U.S. polio vaccine policy?

48

You might also like